“With the official approval of the COVID-19 and influenza combo kit in the US, we plan to not only achieve a large-scale turnaround this year, but also launch new products such as continuous glucose monitors and thermal PCR devices in the market one after another.” (Kang Cheol-hoon, CEO of Osang Healthcare) Osang Healthcare is gearing up for a performance rebound by leveraging the world's first COVID-19 and influenza combo kit to receive formal approval from the US Food and Drug Administration (FDA) 510(k). The company recorded its highest-ever sales in 2023, the COVID-19 endemic period, thanks to the effect of US government bids for diagnostic kits. Although performance plummeted last year as government tender volumes disappeared, the company has fired the starting gun for a rebound through distribution agreements with global giants following the formal approval of the combo kit. Additionally, it is poised to enhance its competitiveness through a diversified portfolio by launching new products in the biochemical field following aggressive investments.
|
News Articles
Osang Healthcare: “Combination kit approved in the US will bring profits this year... Continuous glucose monitor to be commercialized next year”
Jan 20, 2025
